AR039123A1 - Composicion farmaceutica estable que contiene el factor viii - Google Patents

Composicion farmaceutica estable que contiene el factor viii

Info

Publication number
AR039123A1
AR039123A1 ARP030101024A ARP030101024A AR039123A1 AR 039123 A1 AR039123 A1 AR 039123A1 AR P030101024 A ARP030101024 A AR P030101024A AR P030101024 A ARP030101024 A AR P030101024A AR 039123 A1 AR039123 A1 AR 039123A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
factor viii
composition containing
stable pharmaceutical
containing factor
Prior art date
Application number
ARP030101024A
Other languages
English (en)
Inventor
Mary White
Paul Webb
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR039123A1 publication Critical patent/AR039123A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composición farmacéutica sólida estable que comprende el factor VIII. Tal composición carece de aminoácidos y comprende: a) factor VIII; b) un tensioactivo, c) Cloruro de calcio, d) sacarosa, e) Cloruro de sodio, f)citrato trisódico; y g) un búfer; y tiene un pH de 6 a 8 antes de la liofilización y luego de la reconstitución en agua para inyección. Composición farmacéutica líquida que puede obtenerse luego de diluir dicha composición farmacéutica sólida estable con agua estéril con contenido opcional de cloruro de sodio.
ARP030101024A 2002-03-26 2003-03-25 Composicion farmaceutica estable que contiene el factor viii AR039123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0207092.8A GB0207092D0 (en) 2002-03-26 2002-03-26 Stable pharmaceutical composition containing factor VIII

Publications (1)

Publication Number Publication Date
AR039123A1 true AR039123A1 (es) 2005-02-09

Family

ID=9933726

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101024A AR039123A1 (es) 2002-03-26 2003-03-25 Composicion farmaceutica estable que contiene el factor viii

Country Status (27)

Country Link
US (1) US7790680B2 (es)
EP (2) EP1490095B1 (es)
JP (4) JP2005530714A (es)
KR (1) KR20040093482A (es)
CN (2) CN1642570B (es)
AR (1) AR039123A1 (es)
AT (1) ATE477814T1 (es)
AU (1) AU2003217030B2 (es)
BR (1) BR0308442A (es)
CA (1) CA2480226C (es)
DE (1) DE60333825D1 (es)
DK (1) DK1490095T3 (es)
ES (1) ES2350337T3 (es)
GB (1) GB0207092D0 (es)
HK (2) HK1080713A1 (es)
HR (1) HRP20040882B1 (es)
IL (2) IL163849A0 (es)
IS (1) IS7458A (es)
MX (1) MXPA04009275A (es)
MY (1) MY149831A (es)
NO (1) NO328450B1 (es)
NZ (1) NZ535032A (es)
PL (1) PL208009B1 (es)
PT (1) PT1490095E (es)
RU (1) RU2314825C2 (es)
TW (1) TWI285106B (es)
WO (1) WO2003080108A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560107B2 (en) 1996-06-26 2009-07-14 Emory University Modified factor VIII
AU2003285075B2 (en) * 2002-10-29 2009-10-29 Durect Corporation Stabilized, solid-state polypeptide particles
US7485291B2 (en) 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
JP2007534633A (ja) * 2003-11-10 2007-11-29 アライバ−プロメティック インコーポレイティド ヒト・アルファ１−抗トリプシン製剤
EP1750733B1 (en) 2004-05-03 2013-12-11 Emory University METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII
AU2009240026B2 (en) 2008-04-21 2014-05-29 Novo Nordisk Health Care Ag Dry transglutaminase composition
EP2113564A1 (en) 2008-05-01 2009-11-04 Arecor Limited Protein formulation
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
WO2010026186A1 (en) * 2008-09-03 2010-03-11 Octapharma Ag New protecting compositions for recombinantly produced factor viii
BRPI0921429B1 (pt) 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
DK2635297T3 (da) 2010-11-05 2019-05-06 Baxalta GmbH En ny variant af antihæmofil faktor viii, der har en øget specifik aktivitet
JP2016518321A (ja) * 2013-03-15 2016-06-23 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組み換え因子ｖｉｉｉ配合物
JP6330026B2 (ja) 2013-03-15 2018-05-23 バイオベラティブ セラピューティクス インコーポレイテッド 第ｖｉｉｉ因子ポリペプチド製剤
PL3177317T3 (pl) 2014-08-04 2020-07-27 Csl Limited Formulacja czynnika viii
EP3207936B1 (en) * 2014-11-18 2021-04-21 Shionogi & Co., Ltd. Stable peptide composition
CN114072420B (zh) 2019-07-04 2024-06-11 康诺贝林伦瑙有限公司 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf)
US20220380439A1 (en) 2020-11-09 2022-12-01 Takeda Pharmaceutical Company Limited Purification of fviii from plasma using silicon oxide adsorption

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281327A (ja) * 1985-10-04 1987-04-14 Green Cross Corp:The 人トロンビン製剤の加熱処理方法
JPS6485927A (en) 1987-09-29 1989-03-30 Green Cross Corp Hepatitis b vaccine
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
WO1989009784A1 (en) * 1988-04-08 1989-10-19 Commonwealth Serum Laboratories Commission Production of heat-stable factor viii concentrate
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
IE64738B1 (en) * 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
KR100303872B1 (ko) 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
SE9301581D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
ZA955642B (en) * 1994-07-07 1997-05-06 Ortho Pharma Corp Lyophilized imaging agent formulation
JPH0899999A (ja) 1994-09-30 1996-04-16 Chemo Sero Therapeut Res Inst α１プロテアーゼインヒビターの製造方法
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1154796B1 (en) * 1999-02-22 2007-06-20 University of Connecticut Novel albumin-free factor viii formulations
EP1194161B1 (en) * 1999-07-13 2005-11-23 Biovitrum Ab Stable factor viii compositions
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
JP2003507388A (ja) * 1999-08-17 2003-02-25 ノボ ノルディスク アクティーゼルスカブ 凍結乾燥したケーキの安定化
US7576182B1 (en) * 1999-08-31 2009-08-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Also Published As

Publication number Publication date
NO20044305L (no) 2004-10-11
MXPA04009275A (es) 2005-01-25
HK1183446A1 (en) 2013-12-27
TW200304827A (en) 2003-10-16
CN1642570A (zh) 2005-07-20
PL372414A1 (en) 2005-07-25
JP2011079862A (ja) 2011-04-21
EP2292216A2 (en) 2011-03-09
JP5770775B2 (ja) 2015-08-26
DK1490095T3 (da) 2010-11-08
CN103006540A (zh) 2013-04-03
US20050256038A1 (en) 2005-11-17
NO328450B1 (no) 2010-02-22
ES2350337T3 (es) 2011-01-21
EP2292216A3 (en) 2011-05-11
NZ535032A (en) 2006-03-31
EP1490095B1 (en) 2010-08-18
MY149831A (en) 2013-10-31
PT1490095E (pt) 2010-10-21
GB0207092D0 (en) 2002-05-08
KR20040093482A (ko) 2004-11-05
EP1490095A1 (en) 2004-12-29
JP2013147508A (ja) 2013-08-01
JP2015143245A (ja) 2015-08-06
DE60333825D1 (de) 2010-09-30
WO2003080108A1 (en) 2003-10-02
HK1080713A1 (en) 2006-05-04
CA2480226A1 (en) 2003-10-02
PL208009B1 (pl) 2011-03-31
AU2003217030B2 (en) 2008-12-04
TWI285106B (en) 2007-08-11
BR0308442A (pt) 2005-01-18
CN1642570B (zh) 2013-01-09
RU2004131556A (ru) 2005-08-20
RU2314825C2 (ru) 2008-01-20
ATE477814T1 (de) 2010-09-15
IL163849A (en) 2010-12-30
CA2480226C (en) 2012-09-18
IS7458A (is) 2004-09-17
HRP20040882B1 (hr) 2013-02-28
IL163849A0 (en) 2005-12-18
CN103006540B (zh) 2015-09-16
AU2003217030A1 (en) 2003-10-08
US7790680B2 (en) 2010-09-07
HRP20040882A2 (en) 2004-12-31
JP2005530714A (ja) 2005-10-13

Similar Documents

Publication Publication Date Title
AR039123A1 (es) Composicion farmaceutica estable que contiene el factor viii
AR117403A2 (es) Formulaciones de anticuerpos
AR110731A2 (es) Formulaciones que estabilizan e inhiben la precipitación de composiciones inmunogénicas
AR112443A2 (es) Un kit para reconstitución o dilución de un fármaco
AR092919A2 (es) Composicion farmaceutica liquida
AR078885A2 (es) Composiciones estabilizadas de proteinas que tienen un radical tiol libre. recipiente impermeable. metodo.
AR040881A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-alfa
ECSP045496A (es) "preparaciones acidas de insulina con estabilidad mejorada"
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
AR078558A1 (es) Excipiente estabilizante para una vacuna de virus completo inactivado
CO5660273A2 (es) Formulaciones de proteina y anticuerpo de alta concentracion
FI971486A0 (fi) Alfa-interferonin stabiilit vesiliuosformulaatiot
DE60233137D1 (de) Transporter mit beabstandeten arginin-teilchen
AR040527A1 (es) Formulaciones de hgh en alta concentracion que contienen glicina
NO934355L (no) Proteinformulering omfattende veksthormon
AR043863A1 (es) Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines
PE20130579A1 (es) Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa
CO6290629A2 (es) Composiciones de limpieza de amino ácido básico y métodos
DE602004015725D1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
AR116112A2 (es) COMPOSICIÓN FARMACÉUTICA LÍQUIDA CON ESTABILIDAD EN EL LARGO PLAZO DE UN FACTOR VON WILLEBRAND (rVWF) RECOMBINANTE
BR9908479A (pt) Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio
BRPI0606119A2 (pt) preparações injetáveis de diclofenaco e seus sais farmaceuticamente aceitáveis
AR037131A1 (es) Formulaciones de jarabe de ribavirina
ATE268590T1 (de) Pharmazeutische emulsion enthaltend sorbinsäure, na-edta und borsäure
CO5150215A1 (es) Composiciones que tienen estabilidad mejorada

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FC Refusal